Effect of cyclic maintenance therapy on the duration of complete remission and survival of acute leukemia is reported.
Cyclic maintenance therapy was composed of administration of one of the following drugs at one time for the period of 4 weeks: 6MP 2.5 mg/kg/day orally, cyclophosphamide 2.5 mg/kg/day orally, prednisolone 30 mg/day orally, methotrexate 2.5 to 5.0 mg/day orally or 10 to 15 mg twice a week orally, or cytosine arabinoside 40 to 200 mg twice a week intravenously. The maintenance therapy was instituted after complete remission was obtained with various remission induction treatment.
During the 5 year period for 1965 through 1969, 25 patients with acute leukemias (13 myeloblastic, 2 paramyeloblastic, 1 monocytic and 9 lymphocytic) were treated with cyclic use of drugs for their remission maintenance. Control groups consisted of 22 cases of 6 MP maintenance and 36 cases of non-maintenance; only those whose remissions lasted longer than 4 weeks were selected to match the cyclic maintenance group.
The median duration of complete remission for cyclic, 6 MP and non-maintenance groups was 11 1/3, 4 2/3 and 2 months, respectively. Differences between each of the 3 groups are statistically significant. The median survival for the 3 groups was, in the same order, 19, 10 1/3 and 8 1/3 months, respectively. The difference of survival time between cyclic and 6 MP maintenance groups is highly significant but that between 6 MP and non-maintenance groups is not significant. Namely, cyclic maintenance therapy attained the prolongation of survival of acute leukemia patients, which 6 MP maintenance therapy could not.
Side effects of cyclic maintenance therapy were minimal and easy controlable. No interruption of the therapy was necessary.
The marked life-prolonging effect of cyclic maintenance therapy also is well reflected in the analysis of a total of 94 acute leukemia cases treated in the same 5 year period. More than 10 per cent of the patients (12) survived longer than 2 years. The median survival is 5 1/3 versus 3 1/3 months for the 100 cases treated during the preceding 5 years. Twenty per cent survival was 14 2/3 versus 8 1/3 months.
Thus, cyclic maintenance therapy described here is practical and effective way of maintenance therapy of complete remission in acute leukemia.
View full abstract